Atezolizumab is a highly specific humanized IgG1 antibody, that can block the interaction of PD-L1 ligand expressed on tumor cells with the PD-1 receptors on T-cell population thereby reducing the immunosuppressive action of tumor inducing cells and enhancing the adaptive immune responses in the host against tumors [11]. This evidence concerns the gene CD274 and neoplasm.